4.33
0.00%
0.00
Geron Corp stock is traded at $4.33, with a volume of 7.33M.
It is up +0.00% in the last 24 hours and down -1.37% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$4.33
Open:
$4.29
24h Volume:
7.33M
Relative Volume:
0.84
Market Cap:
$2.61B
Revenue:
$237.00K
Net Income/Loss:
$-184.13M
P/E Ratio:
-12.74
EPS:
-0.34
Net Cash Flow:
$-168.57M
1W Performance:
+0.23%
1M Performance:
-1.37%
6M Performance:
+14.85%
1Y Performance:
+134.05%
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Geron Corp Stock (GERN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Apr-29-24 | Initiated | TD Cowen | Buy |
Mar-15-24 | Reiterated | Needham | Buy |
Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
Mar-28-23 | Initiated | Goldman | Neutral |
Oct-28-22 | Initiated | Wedbush | Outperform |
Jul-28-22 | Resumed | B. Riley Securities | Buy |
Nov-02-21 | Initiated | Robert W. Baird | Outperform |
Feb-18-21 | Resumed | B. Riley Securities | Buy |
Aug-03-20 | Initiated | Stifel | Buy |
Nov-19-19 | Resumed | B. Riley FBR | Buy |
Sep-03-19 | Initiated | H.C. Wainwright | Buy |
Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
Apr-09-19 | Upgrade | Needham | Hold → Buy |
Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
Sep-13-16 | Reiterated | FBR & Co. | Outperform |
Sep-13-16 | Reiterated | FBR Capital | Outperform |
Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
Apr-21-15 | Initiated | Oppenheimer | Outperform |
Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
Dec-10-13 | Reiterated | MLV & Co | Buy |
Dec-10-13 | Upgrade | Needham | Hold → Buy |
Nov-08-13 | Reiterated | MLV & Co | Buy |
Oct-16-13 | Initiated | MLV & Co | Buy |
Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Leerink maintains Outperform rating on Geron shares - Investing.com
Leerink maintains Outperform rating on Geron shares By Investing.com - Investing.com UK
Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential? - Insider Monkey
Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential? - Yahoo Finance
Geron Corp (GERN) Q2 2024 Earnings Call Highlights: Strong Financial Position Amid Early Rytelo ... - Yahoo Finance UK
Wall Street Analysts Rate Geron Corporation (GERN) as a Buy Amid Strong Growth Prospects - Insider Monkey
Wall Street Analysts Rate Geron Corporation (GERN) as a Buy Amid Strong Growth Prospects - Yahoo Finance
Geron (NASDAQ:GERN) Trading 4.1% HigherTime to Buy? - MarketBeat
The Manufacturers Life Insurance Company Acquires 553,081 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Corporation (GERN): A Hot Stock to Buy Now - Yahoo Finance
Algert Global LLC Takes $539,000 Position in Geron Co. (NASDAQ:GERN) - MarketBeat
10 Best Biotech Stocks To Buy Under $20 - Insider Monkey
Goldman Sachs maintains Buy rating on Geron - Investing.com
Is Geron Corporation (GERN) the Best NASDAQ Stock Under $5? - Insider Monkey
Is Geron Corporation (GERN) the Best NASDAQ Stock Under $5? - Yahoo Finance
When Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)? - Yahoo Finance
Geron's SWOT analysis: biotech firm's stock rides on Rytelo success - Investing.com
Renaissance Technologies LLC Takes $3.32 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
7 Best NASDAQ Stocks Under $5 - Insider Monkey
Nasdaq Composite [TR] (XCMP) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
Darwin Global Management Ltd. Acquires Shares of 23,915,480 Geron Co. (NASDAQ:GERN) - MarketBeat
Positive early demand trends for Geron’s Rytelo lead Goldman Sachs to reaffirm Buy rating - Investing.com
Affinity Asset Advisors LLC Sells 1,000,000 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Farallon Capital Management LLC Has $71.39 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
Regeneron slides as Amgen wins Eylea biosimilar case; RBC still bullish - Investing.com
Groupon (GRPN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Geron: Derisked And Highly Attractive After Approval - Seeking Alpha
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
GERN’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Geron Corp. [GERN] moved down -0.63: Why It’s Important - The DBT News
Regeneron Pharmaceuticals’ (REGN) Overweight Rating Reiterated at Wells Fargo & Company - Defense World
Groupon Inc [GRPN] Investment Appeal on the Rise - Knox Daily
Geron (NASDAQ:GERN) Stock Price Down 4.5% - MarketBeat
337,752 Shares in GE Vernova Inc. (NYSE:GEV) Acquired by Gladstone Capital Management LLP - Defense World
Smart Money Is Betting Big In REGN Options - Benzinga
Head to Head Contrast: Mirage Energy (OTCMKTS:MRGE) vs. Gibson Energy (OTCMKTS:GBNXF) - Defense World
GoodRx Holdings Inc (GDRX)’s Market Momentum: Closing Strong at 6.91, Down -2.40 - The Dwinnex
Xponance Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Balance Sheet Breakdown: Rigetti Computing Inc (RGTI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
40 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Itau Unibanco Holding S.A. - Defense World
Examining Gorilla Technology Group Inc (GRRR) more closely is necessary - US Post News
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week Low at $24.36 - Defense World
Morse Asset Management Inc Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Gabelli Funds LLC Takes $16.80 Million Position in GE Vernova Inc. (NYSE:GEV) - Defense World
Tri Locum Partners LP Purchases 46,577 Shares of argenx SE (NASDAQ:ARGX) - MarketBeat
GM Stock Is Falling After Downgrade by Former Bull - Barron's
Genel Energy Solidifies Leadership, Eyes Growth - TipRanks
Adversity is less terrifying than hope: Genesis Energy L.P. (GEL) - SETE News
Brighton Jones LLC Acquires Shares of 2,103 GE Vernova Inc. (NYSE:GEV) - Defense World
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Option Exercise |
1.72 |
674,348 |
1,159,879 |
674,348 |
GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
LAWLIS V BRYAN | Director |
May 15 '24 |
Option Exercise |
1.94 |
35,000 |
67,900 |
35,000 |
LAWLIS V BRYAN | Director |
May 15 '24 |
Sale |
3.75 |
35,000 |
131,250 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):